Tiaspirone in schizophrenia.

Abstract

It was predicted that tiaspirone, a novel compound, would benefit schizophrenic patients since in animal experiments it is a potent dopamine blocker. Following a placebo washout period of 1 to 2 weeks, 14 patients were treated for 28 days with the drug in a single-blind, dose ranging trial. GAS, NOSIE, and BPRS scores all showed significant improvement. No serious adverse effects were found. The absence of extrapyramidal symptoms was particularly encouraging since 10 of the 14 subjects had previously had them on other neuroleptics. Tiaspirone may represent a step forward in the search for a safer antipsychotic.

• Authors: N C Moore, E Meyendorff, V Yeragani, P A LeWitt, S Gershon
• Journal: Journal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 7 Issue 2 Pg. 98-101 (Apr 1987) ISSN: 0271-0749 [Print] United States
• PMID: 3294920 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Psychotropic Drugs
• Spiro Compounds
• tiospirone
• L-Lactate Dehydrogenase

Topics

• Adolescent
• Adult
• Clinical Trials as Topic
• Humans
• Hypotension, Orthostatic (chemically induced)
• L-Lactate Dehydrogenase (blood)
• Liver (drug effects, enzymology)
• Male
• Middle Aged
• Psychotropic Drugs (therapeutic use)
• Schizophrenia (drug therapy)
• Spiro Compounds (adverse effects, therapeutic use)